On CNBC’s "Mad Money Lightning Round," Jim Cramer said ADMA Biologics, Inc. ADMA is a "great spec, but it is losing money hand over fist. I think it’s very binary. I can not like binary situations."
Analysts disagree, according to Benzinga data, ADMA has a consensus Buy rating.
When asked about Rite Aid Corporation RAD, he said, "We don’t want Rite Aid. Why don’t we buy CVS Health Corporation CVS?"
Cramer said he likes WESCO International WCC very much. "I think you have a winner," he added.
When asked about AT&T Inc. T, Cramer said, "T-Mobile US, Inc. TMUS is the class of the field." AT&T is not as bad as it used to be, he added.
Don’t forget to check out our premarket coverage here .
The "Mad Money" host said he prefers Sempra SRE over NextDecade Corporation NEXT.
When asked about Array Technologies, Inc. ARRY, he said, "If they make the money that they’re supposed to make this year, then I think you’ll be in very good shape."
Cramer said FREYR Battery FREY is losing too much money. "That’s too tough," he added.
Now Read This: $3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying
Photo: Courtesy of Scott Beale on flickr
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.